Eli Lilly to Seek FDA Approval for Obesity Drug

Published on October 6, 2022

Eli Lilly has exciting news! They’re getting closer to obtaining FDA approval for their obesity drug tirzepatide. Just like a rocket blasting off into space, this drug is making great strides on its journey to combat obesity. The company plans to submit their application to the FDA in stages, like a puzzle slowly coming together. If all goes well, this new drug could be a game-changer in the fight against obesity. Tirzepatide works by targeting receptors in the brain that regulate appetite and glucose metabolism. By doing so, it helps control food intake and improves blood sugar levels for those struggling with weight management and type 2 diabetes. With obesity rates skyrocketing, it’s crucial to have effective medications on the market. Eli Lilly’s efforts to seek FDA approval for tirzepatide demonstrate their commitment to developing innovative treatments. To learn more about the latest research and developments in this field, dive into the comprehensive article provided!

Eli Lilly and Co. said Thursday it plans to start a rolling submission to the U.S. Food and Drug Administration (FDA) this year to get an approval for its obesity drug tirzepatide.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>